![Logo for Inozyme Pharma Inc](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2Fef81d-2024-07-03-11-57-58.png&w=256&q=100)
Inozyme Pharma Investor Relations Material
Latest events
![Logo for Inozyme Pharma Inc](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2Fef81d-2024-07-03-11-57-58.png&w=128&q=100)
Study Update
Inozyme Pharma
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Inozyme Pharma Inc
Access all reports
Inozyme Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases that affect the vasculature, soft tissue, and skeleton. The company's research is centered on disorders related to the PPi-Adenosine Axis, a pathway crucial for mineralization and vascular health. Disruptions in this pathway can lead to severe conditions such as ENPP1 and ABCC6 deficiencies, which Inozyme targets with its lead product candidate, INZ-701. This enzyme replacement therapy is designed to address pathologic mineralization and intimal proliferation, aiming to reduce the morbidity and mortality associated with these conditions. The company is headquartered in Boston, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Inozyme Pharma Inc
![Burden of ENPP1 Defi](/_next/image?url=https%3A%2F%2Fcdn.quartr.com%2Fimages%2Fconference-calls%2Finozyme-pharma-inc-study-result-a828f1bc9655423b%2F5.png&w=3840&q=75)
![Logo for Inozyme Pharma Inc](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2Fef81d-2024-07-03-11-57-58.png&w=128&q=100)
Study Result
Inozyme Pharma Inc
![INZ - 701 showed con](/_next/image?url=https%3A%2F%2Fcdn.quartr.com%2Fimages%2Fconference-calls%2Finozyme-pharma-inc-study-result-a828f1bc9655423b%2F17.png&w=3840&q=75)
![Logo for Inozyme Pharma Inc](/_next/image?url=https%3A%2F%2Ffiles.quartr.com%2Fcompany-logos%2Fef81d-2024-07-03-11-57-58.png&w=128&q=100)
Study Result
Inozyme Pharma Inc
Latest articles
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2Fbbbaafadba%2Fpontis-dackmo_strong-opinions-loosely-held.png&w=3840&q=75)
Strong Opinions, Loosely Held: Pontus Dackmo on Flexibility and Market Psychology
After a two-decade career in finance, Pontus Dackmo co-founded Protean Funds Scandinavia in 2022, where he now serves as CEO and Investment Manager.
4 Sep 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F7455f6afd1%2Fnovo-nordisk_the-danish-pharmaceutical-titan.png&w=3840&q=75)
Novo Nordisk: The Danish Pharmaceutical Titan Revolutionizing Global Healthcare
Novo Nordisk's rise to becoming Europe's largest company, reshaping global healthcare and Denmark's economy.
5 Sep 2024
![Key](/_next/image?url=https%3A%2F%2Fa.storyblok.com%2Ff%2F182663%2F2000x1125%2F5533bee49f%2Fthe-toyota-way.png&w=3840&q=75)
The Toyota Way: Revolutionizing Global Manufacturing
Explore how Toyota's Lean Manufacturing and Kaizen principles revolutionized production and quality, setting global benchmarks for excellence.
2 Sep 2024
Ticker symbol
INZY
Country
🇺🇸 United States